MedTrace Logo

An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers

NCT03724292 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-10-30

No results posted yet for this study

Summary

This is Part 1 of a two-part, randomized, double-blind, placebo-controlled study in which VTP-43742 was administered to participants; Part 1 in healthy volunteers and Part 2 in psoriatic participants.

Conditions

Interventions

DRUG

Placebo

Dose-matched placebo administered as oral capsule(s) once daily

DRUG

VTP-43742

VTP-43742 administered as oral capsule(s) once daily

Sponsors & Collaborators

  • Vitae Pharmaceuticals Inc., an Allergan affiliate

    lead INDUSTRY

Principal Investigators

  • Richard Gregg, MD · Vitae Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-08-01
Primary Completion
2016-03-08
Completion
2016-03-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03724292 on ClinicalTrials.gov